Co-diagnostics, INC

Co-Diagnostics, Inc. has entered into an agreement to induce holders of existing warrants to exercise them for cash, in exchange for issuing new warrants, aiming to raise approximately $2.67 million.

Co-Diagnostics, Inc. has amended its equity distribution agreement with Maxim Group LLC, removing the fixed aggregate dollar limitation on future stock sales.

Co-Diagnostics, Inc. announced a $3.0 million private placement of common stock and warrants, aiming to bolster general corporate purposes and working capital.

Co-Diagnostics announced its first quarter 2026 financial results, highlighting regulatory progress in India, expanded distribution in South Asia, and continued investment in R&D.

Co-Diagnostics, Inc. announced full year 2025 financial results, reporting a significant revenue decline and increased net loss, while highlighting progress in global joint ventures and clinical pipeline.

Co-Diagnostics, Inc. received notice from Nasdaq regarding the delisting of its common stock due to non-compliance with the minimum bid price rule, with trading suspension effective January 14, 2026.

Co-Diagnostics reports a wider net loss for Q1 2026 due to increased R&D spending and lower other income, despite a rise in product revenue.

Co-Diagnostics reported a significant revenue decline and increased operating cash burn, leading to a 'going concern' warning despite recent capital raises.

Co-Diagnostics reports significant revenue decline and increased operating losses, raising substantial doubt about its ability to continue as a going concern while facing NASDAQ delisting risk.

Co-Diagnostics, Inc. reports a decrease in revenue for Q1 2025 compared to Q1 2024, while continuing to focus on the development and regulatory approval of its Co-Dx PCR platform.

Co-Diagnostics experienced a decrease in revenue for the third quarter of 2024, primarily due to a reduction in grant funding and product sales, while also seeing a net loss increase.

Co-Diagnostics saw a significant increase in revenue in the second quarter of 2024, primarily due to grant funding, while also experiencing a reduced net loss compared to the same period last year.

Co-Diagnostics, Inc. files its annual report on Form 10-K, detailing financial results for 2024 and announcing the withdrawal of its FDA 510(k) submission for its at-home COVID-19 PCR test.

Co-Diagnostics, Inc.'s annual 10-K filing details its capital structure, ongoing development of its PCR platform, and regulatory submissions, while also acknowledging a significant revenue decline due to reduced COVID-19 test sales.

Dwight H. Egan, CEO of Co-Diagnostics, Inc., reported transactions involving restricted stock units and common stock.

Co-Diagnostics CFO Brian Lee Brown reports transactions involving restricted stock units and common stock, including a sale to cover tax withholding obligations.

Richard David Abbott, President of Co-Diagnostics, Inc., reported transactions involving restricted stock units and common stock, including a sale to cover tax withholding obligations.

Edward L. Murphy, a Director at Co-Diagnostics, Inc., reported transactions involving restricted stock units and common stock.

Richard S. Serbin, a Director at Co-Diagnostics, Inc., reported a transaction involving the acquisition of 1,695 shares of common stock on May 23, 2026.

Eugene Durenard, a Director at Co-Diagnostics, Inc., reported transactions involving restricted stock units and common stock.

Co-Diagnostics, Inc. announced its 2026 Annual Meeting of Shareholders, scheduled for September 3, 2026, and is seeking shareholder approval to increase the number of shares available under its 2025 Equity Incentive Plan.

Co-Diagnostics, Inc. will hold a Special Meeting on December 5, 2025, to seek shareholder approval for a reverse stock split to maintain its Nasdaq listing.

Co-Diagnostics is holding its annual shareholder meeting on May 28, 2025, to vote on director elections, adoption of a new equity incentive plan, executive compensation, and ratification of the company's accounting firm.

Co-Diagnostics, Inc. will hold its virtual-only Annual Meeting of Shareholders on August 29, 2024, to vote on director election, executive compensation, auditor ratification, and other business.

Jane Street Group, LLC, Jane Street Capital, LLC, and Jane Street Global Trading, LLC have collectively reported beneficial ownership of 6.4% of Co-Diagnostics, Inc. common stock.

Ayrton Capital LLC and its affiliates have reported a complete divestment of their beneficial ownership in Co-Diagnostics, Inc., now holding 0% of the common stock.

Ayrton Capital LLC, along with Alto Opportunity Master Fund and Waqas Khatri, reported a 9.70% beneficial ownership stake in Co-Diagnostics, Inc. common stock.

Orca Capital AG has filed an amended Schedule 13G, reporting a beneficial ownership of 3.7% of Co-Diagnostics, Inc.'s common stock.

Orca Capital AG has filed an amended Schedule 13G, reporting a 9.9% beneficial ownership stake in Co-Diagnostics, Inc.

The Vanguard Group has filed an amendment to its Schedule 13G, reporting a 3.54% beneficial ownership in Co-Diagnostics Inc.